financetom
Business
financetom
/
Business
/
Cuts to USAID halt US farm research at universities, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cuts to USAID halt US farm research at universities, sources say
Feb 12, 2025 11:18 AM

(Reuters) - The Trump administration's dismantling of the U.S. Agency for International Development has halted work at a network of farm research laboratories at land grant universities in 13 states, according to six lab directors.

The lab closures are another hit to U.S. agriculture from President Donald Trump's overhaul of the federal government, by blocking research work designed to advance seed and equipment technology and develop markets abroad for U.S. commodities. 

Farmers have already seen disruptions to government food purchases for aid, and to agricultural grant and loan programs.

Land-grant universities were founded on land given to states by the federal government.

"For U.S. farmers, this is not good," said Peter Goldsmith, who leads the University of Illinois' Soybean Innovation Lab, one of the affected labs.      

The State Department did not respond to a request for comment.  

The network of 17 laboratories was funded by USAID through a program called Feed the Future Innovation Labs, and pursued research in partnership with countries such as Malawi, Tanzania, Bangladesh, and Rwanda, the lab directors said.  

Their research helps U.S. farmers because programs conducted overseas can develop production practices that may be useful in the U.S. or provide advance warning of pests, directors said. 

"It really reduces our capacity to help farmers fight pests and diseases and help American farmers prevent incursions," said David Hughes, director of the USAID Innovation Lab on Current and Emerging Threats to Crops at Penn State University.

One study that has been halted was working to control a viral disease spread by an aphid that was hurting banana crops in Tanzania, Hughes said.

David Tschirley, who runs an agency-funded lab at Michigan State University and is chair of the Feed the Future Innovation Lab Council, which represents the lab network, said about 300 people are employed by the labs, and they have as many as 4,000 collaborators abroad.

"It presents an American face to the world that is a very appreciated face," he said, adding that such work benefits national security.

STOP-WORK ORDERS

All 17 labs received stop-work orders at the end of January after Trump froze most foreign aid, and have not received additional guidance or responses to queries from the State Department, which oversees USAID, Tschirley said.  Some labs are petitioning their host universities to cover some costs, with mixed success, the lab directors said. 

Michigan State is allowing Tschirley's lab to keep employees based on the expectation USAID will eventually approve the costs, he said.

Goldsmith said he laid off all 30 staff at his lab last week, and plans to close it on April 15. He said his lab has provided technical assistance to farmers planting soy in African countries and to companies building soy-processing plants.  

Some of that lab's partners have included agribusiness companies Bayer, Corteva, BASF, and Archer-Daniels-Midland, according to a 2020 report on the lab's website. 

Bayer, one of the world's biggest producers of crop seeds and chemicals, said it was assessing the funding halt. The other companies declined to comment or did not respond to questions.

Some of Trump's other actions to reshape government have also affected U.S. farmers. Tens of millions of dollars of U.S. commodity purchases, for example, were temporarily halted after the Trump administration's January 24 order freezing most foreign aid.     

 Farmers across the country also say they are not receiving payments from a range of federal farm programs under Trump's directive to freeze federal loans and grants, which has been blocked in court.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
National Bank of Canada Neutral On Lundin Gold's Updated Reserve Estimate
National Bank of Canada Neutral On Lundin Gold's Updated Reserve Estimate
Apr 1, 2024
11:18 AM EDT, 04/01/2024 (MT Newswires) -- National Bank of Canada over the weekend ascribed a neutral bias to Lundin Gold's ( LUGDF ) updated reserve and resource estimate for year-end 2023. The estimate outlined reserves of 5.5 million ounces of gold grading 7.89 g/t gold as of Dec. 31, 2023, increasing from 5.0 million ounces at 8.68 g/t gold...
Doximity Business Under Pressure as Underlying Sales Falling, Jehoshaphat Research Says
Doximity Business Under Pressure as Underlying Sales Falling, Jehoshaphat Research Says
Apr 1, 2024
11:21 AM EDT, 04/01/2024 (MT Newswires) -- Doximity ( DOCS ) business is under pressure because of multiple reasons including declining underlying sales, Jehoshaphat Research said in a note to clients. The research firm believed that the company's underlying sales are falling at a negative 3% to 6% rate, the report added. Senior executives' departure from the company, including the...
Update: United Airlines Asks Pilots to Take Unpaid Leave Due to Delayed Boeing Deliveries
Update: United Airlines Asks Pilots to Take Unpaid Leave Due to Delayed Boeing Deliveries
Apr 1, 2024
11:21 AM EDT, 04/01/2024 (MT Newswires) -- (Updates with United Airlines' confirmation and comment in the first and second paragraphs.) United Airlines (UAL) said Monday it is asking pilots to take voluntary unpaid time off in May due to delays in Boeing ( BA ) aircraft deliveries. We can confirm that due to the recent delays in Boeing ( BA...
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Apr 1, 2024
April 1 (Reuters) - Teva Pharmaceutical and Viatris ( VTRS ) convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson ( JNJ ) schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine. The U.S. Court of Appeals for the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved